Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma

Kyu Sang Lee, Gheeyoung Choe, Sumi Yun, Kyoungyul Lee, Seyoung Moon, Sangchul Lee, Sung Kyu Hong, Seok Soo Byun, Sang Eun Lee

Research output: Contribution to journalArticle

Abstract

Aims: The importance of programmed cell death ligand 1 (PD-L1) expression has emerged in clinical trials of PD-L1 target therapy in renal cell carcinoma (RCC). This study compares PD-L1 assays in RCC. Methods and results: Two US Food and Drug Administration-approved PD-L1 assays (22C3 and SP142) and one research-use only antibody (E1L3N) were used in a retrospective cohort of 591 patients with RCC. PD-L1 positivity on tumour cells (TCs) and immune cells (ICs) and combined positive score (CPS) were evaluated. With the 22C3, SP142 and E1L3N assays, positive PD-L1 expression on TCs ≥1% was observed in 24 (4.1%), 12 (2.0%) and 16 (2.7%) cases and on ICs ≥1% was observed in 132 (22.3%), 120 (20.3%) and 65 (11.0%) cases, respectively. PD-L1 expression scores among the three assays showed moderate–high positive correlation (ρ = 0.599–0.835, P < 0.001). Assays appeared similar, although staining in ICs was comparatively less frequent with E1L3N. 22C3 showed frequent positivity in TCs. PD-L1 expression on TCs was associated with papillary type 2 RCC (P < 0.001). IC infiltration and PD-L1 expression on ICs were predominantly found in clear cell and papillary type 1 RCC (P < 0.05). Conclusions: Programmed death 1 (PD-1)/PD-L1 target therapy may be beneficial for patients with papillary type 2 RCC, even if they are categorised as a heterogeneous group. PD-L1 assays should be carefully selected, and accurate histological subtyping of RCC is needed prior to decisions on PD-L1 testing, because of the different PD-L1 expression observed among varying RCC subtypes.

Original languageEnglish
Pages (from-to)67-78
Number of pages12
JournalHistopathology
Volume77
Issue number1
DOIs
StatePublished - 1 Jul 2020

Keywords

  • 22C3
  • SP142
  • immunotherapy
  • programmed cell death ligand 1
  • renal cell carcinoma

Fingerprint Dive into the research topics of 'Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Lee, K. S., Choe, G., Yun, S., Lee, K., Moon, S., Lee, S., Hong, S. K., Byun, S. S., & Lee, S. E. (2020). Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma. Histopathology, 77(1), 67-78. https://doi.org/10.1111/his.14054